Skip to main content

Table 2 Patient demographics, disease parameters, and baseline biomarker serum concentrations from MOBILITY part B biomarker analysis

From: Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

  Placebo + MTX
(n = 128)
Sarilumab 200 mg q2w + MTX
(n = 131)
Totala
(n = 259)
Baseline demographic and disease parameters
 Age, mean ± SD, years 51.1 ± 10.6 49.3 ± 12.3 50.2 ± 11.5
 Sex, female, % 77.3 84.7 81.1
 Duration of RA, mean ± SD, years 9.1 ± 8.2 8.1 ± 6.7 8.6 ± 7.5
 Anti-CCP antibody positive, % 82.8 87.0 84.9
 Rheumatoid factor positive, % 87.5 87.8 87.6
 Tender joint count, mean ± SD 27.3 ± 14.8 25.9 ± 14.5 26.6 ± 14.7
 Swollen joint count, mean ± SD 15.8 ± 8.0 16.6 ± 10.6 16.2 ± 9.4
 CRP, mean ± SD, mg/dL 1.7 ± 1.9 2.1 ± 2.1 1.9 ± 2.0
 mTSS, mean ± SD 51.8 ± 72.1 45.9 ± 60.2 48.8 ± 66.3
Baseline biomarker serum concentrations, median (quartile 1/quartile 3)
 C1M, ng/mL 114.0 (77.0/175.7) 120.5 (86.1/196.3) 119.6 (80.7/184.2)
 C2M, ng/mL 0.3 (0.2/0.4) 0.3 (0.2/0.4) 0.3 (0.2/0.4)
 C3M, ng/mL 43.1 (34.6/58.0) 45.4 (34.4/60.5) 44.2 (34.5/59.9)
 CTX-1, ng/mL 0.4 (0.3/0.6) 0.4 (0.3/0.5) 0.4 (0.3/0.5)
 MMP-3, ng/mL 41.9 (24.6/77.6) 38.9 (21.3/68.7) 40.3 (22.3/73.1)
 OC, ng/mL 18.3 (13.0/25.0) 18.6 (14.6/24.7) 18.5 (13.5/24.7)
 OPG, pmol/L 4.9 (3.9/6.3) 5.4 (3.9/6.7) 5.2 (3.9/6.5)
 sRANKL, pmol/L 1012.5 (385.0/3893.0) 1096.0 (393.0/2161.5) 1026.0 (387.0/2748.5)
 sRANKL/OPG 245.1 (64.4/836.5) 186.3 (71.8/401.2) 212.6 (70.8/509.7)
  1. aAll patients receiving placebo or sarilumab 200 mg q2w. C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, C3M collagen type III MMP-cleaved fragment, CCP cyclic citrullinated peptide, CRP C-reactive protein, CTX-1 carboxy-terminal collagen crosslinks 1, MMP matrix metalloproteinase, mTSS van der Heijde modified total Sharp score, MTX methotrexate, OC osteocalcin, OPG osteoprotegerin, q2w every 2 weeks, RA rheumatoid arthritis, SD standard deviation, sRANKL soluble receptor activator of nuclear factor-kB ligand